enGene Announces Name Change to enGene Therapeutics Inc. and Provides Major Pipeline Updates

Key Developments

• Corporate Name Change: enGene Inc. has announced it will officially change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The new name reflects the company’s transition toward a potential commercial launch, positioning itself as a commercial-stage organization in anticipation of the possible approval of its lead asset, detalimogene voraplasmid, in 2027.
• Upcoming BLA Submission: The company is targeting the submission of a Biologics License Application (BLA) for detalimogene voraplasmid in the second half of 2026, supporting possible commercialization in 2027.
• Ongoing LEGEND Trial: enGene’s pivotal Phase 2 LEGEND trial is evaluating detalimogene voraplasmid in high-risk non-muscle invasive bladder cancer (NMIBC), including patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy and those with carcinoma in situ (CIS).
• Stock and Warrant Details: The company’s shares and warrants will continue trading on Nasdaq under “ENGN” and “ENGNW,” respectively. However, shareholders should note new CUSIP and ISIN numbers will be assigned due to the name change.

Details Investors Need to Know

1. Name Change and Shareholder Impact

The name change to enGene Therapeutics Inc. underscores the company’s shift toward becoming a commercial-stage biotech, as it prepares for the possible market introduction of detalimogene voraplasmid. The change is effective April 8, 2026. Importantly, this action does not affect the rights of existing shareholders, and no further action is required by them. However, new CUSIP and ISIN numbers will be issued for both the common shares (CUSIP: 29286X101, ISIN: CA29286X1015) and the warrants (CUSIP: 29286X119, ISIN: CA29286X1197).

2. Detalimogene Voraplasmid: Commercial and Clinical Outlook

Detalimogene voraplasmid is a novel, non-viral gene therapy candidate developed for high-risk NMIBC patients, specifically those who have not responded to standard BCG therapy. The therapy is designed to be administered directly into the bladder, where it triggers a targeted anti-tumor immune response. Detalimogene leverages enGene’s Dually Derivatized Oligochitosan® (DDX) platform, which aims to overcome limitations of viral-based gene therapies, reduce handling complexity, and streamline manufacturing and administration.

The therapy has already achieved Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA, recognizing its potential to address acute unmet clinical need. It is also participating in the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, designed to fast-track therapies that could provide earlier patient access.

3. Progress of the LEGEND Clinical Trial

The pivotal LEGEND trial is a multi-cohort, Phase 2 study actively enrolling patients across the USA, Canada, Europe, and Asia-Pacific. Its main cohort (Cohort 1) includes 125 patients with high-risk, BCG-unresponsive NMIBC with CIS, with or without papillary disease. Results from this group will underpin the upcoming BLA submission.

Additional cohorts in the study are evaluating detalimogene in:

• Patients with CIS who have never received BCG therapy (Cohort 2a)
• Patients with CIS who have had some BCG exposure but not adequate treatment (Cohort 2b)
• BCG-unresponsive high-risk NMIBC patients with papillary-only disease (Cohort 3)

Why This Matters for Shareholders

• Commercialization Pathway: The company is now on a clear path toward commercial launch in 2027, subject to positive data and regulatory approval—a catalyst that could significantly affect share valuation.
• Regulatory Momentum: RMAT and Fast Track designations increase the probability of regulatory success and faster market access, both of which are typically viewed as highly positive by investors.
• Strong Unmet Need: High-risk NMIBC patients, particularly those unresponsive to BCG, have limited options and face significant risks, including high recurrence rates and possible cystectomy. A novel gene therapy addressing this population could capture a substantial market and drive value.
• Trading Logistics: Shareholders should be aware of the new CUSIP and ISIN numbers but do not need to take action. The trading symbols on Nasdaq remain unchanged.
• Potential Price Sensitivity: Any future announcements about trial results, BLA submission acceptance, or regulatory feedback could be price moving events.

About enGene Therapeutics

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing gene therapies for diseases with high unmet needs, leveraging its proprietary DDX platform for targeted delivery to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid, is positioned to address the significant clinical and economic burden of high-risk NMIBC.

For more information, visit enGene.com.

Forward-Looking Statement Disclaimer

This article contains forward-looking statements regarding enGene Therapeutics Inc., including anticipated regulatory filings, potential approval, and commercial prospects for detalimogene voraplasmid. Actual outcomes may differ materially due to risks and uncertainties, including clinical trial results, regulatory actions, and other factors beyond the company’s control. Investors are advised not to place undue reliance on such statements and to review the company’s filings with regulators for further information. This article does not constitute investment advice.

View enGene Holdings Inc. Historical chart here